Drug
RO5045337
RO5045337 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 6 completed trials
Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
6
100%
Phase Distribution
6
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
6(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
6 of 6 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(6)
Detailed Status
Completed6
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 16 (100.0%)
Trials by Status
completed6100%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_1
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
NCT01677780
completedphase_1
A Study of RO5045337 in Patients With Solid Tumors
NCT01164033
completedphase_1
A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors
NCT00559533
completedphase_1
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
NCT01605526
completedphase_1
A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery
NCT01143740
Clinical Trials (6)
Showing 6 of 6 trials
NCT01677780Phase 1
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
NCT01164033Phase 1
A Study of RO5045337 in Patients With Solid Tumors
NCT00559533Phase 1
A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors
NCT01605526Phase 1
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
NCT01143740Phase 1
A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery
NCT00623870Phase 1
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6